Table 1.
Entire cohort (n=2419) |
With AAU (n=568, 23.5%) |
With psoriasis (n=264, 10.9%) |
With IBD (n=247, 10.2%) |
|
---|---|---|---|---|
Gender (male) | 68.4% | 66.7% | 67.4% | 65.2% |
Age (years), median (IQR) | 47.0 (36.0–59.0) | 51.0 (41.0–61.0) | 51.5 (38–62) | 52.0 (40.0–63.0) |
AxSpA disease duration (years), median (IQR) | 16.0 (7.0–30.0) | 22.0 (11.0–34.0) | 17.5 (7.0–32.0) | 20.0 (8.0–35.0) |
BMI (kg/m2), median (IQR) | 26.8 (23.9–30.7) | 27.3 (24.0–31.0) | 27.7 (24.4–31.4) | 27.1 (24.0–30.8) |
HLA-B27 positive | 80.1% | 88.7% | 66.7% | 71.4% |
University degree | 27.8% | 33.5% | 27.2% | 24.8% |
Ever-smoker | 56.2% | 50.1% | 62.7% | 59.7% |
Ever-drinking alcohol | 93.0% | 94.2% | 94.0% | 92.1% |
AAU, acute anterior uveitis; axSpA, axial spondyloarthritis; BMI, body mass index; HLA, human leukocyte antigen; IBD, inflammatory bowel disease.